---
title: 3-dimensional Versus 2-dimensional Laparoscopy for Hysterectomy
nct_id: NCT04070872
overall_status: UNKNOWN
phase: NA
sponsor: Kangbuk Samsung Hospital
study_type: INTERVENTIONAL
primary_condition: Laparoscopy
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04070872.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04070872"
ct_last_update_post_date: 2019-08-28
last_seen_at: "2026-05-12T07:12:57.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# 3-dimensional Versus 2-dimensional Laparoscopy for Hysterectomy

**Official Title:** 3-dimensional Versus 2-dimensional Laparoscopy for Hysterectomy: a Randomized Controlled Trial

**NCT ID:** [NCT04070872](https://clinicaltrials.gov/study/NCT04070872)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 68
- **Lead Sponsor:** Kangbuk Samsung Hospital
- **Conditions:** Laparoscopy
- **Start Date:** 2019-08-23
- **Completion Date:** 2019-08-23
- **CT.gov Last Update:** 2019-08-28

## Brief Summary

The aim of this study is to compare the surgical outcomes and efficacy of 3-dimensional (3D) versus 2-dimensional (2D) imaging systems in laparoscopic hysterectomy.

## Detailed Description

Laparoscopy is founded as a treatment of choice for benign uterine disease. The advantages of laparoscopic surgery over conventional open surgery are less pain, shorter recovery time, shorter hospital stay, and consequently faster return to normal activity as well as better cosmetic effects. However, laparoscopic surgery is more demanding compared with open surgery because operators should project three-dimensional (3D) field through a two-dimensional (2D) monitor.

However, to date, studies examining the possible benefits and drawbacks of 3D imaging system versus 2D in laparoscopic surgery have brought about conflicting results. Moreover, there have been few studies comparing the surgical outcomes of 3D and 2D laparoscopic laparoscopic hysterectomy. The aim of this study is to compare the surgical outcomes and efficacy of 3-dimensional (3D) versus 2-dimensional (2D) imaging systems in laparoscopic hysterectomy.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Uterine myoma requiring laparoscopic myomectomy
* American Society of Anesthesiologists physical status (ASAPS) classification I-II
* absence of pregnancy at the time of surgery.

Exclusion Criteria:

* any suspicious findings of malignant gynecologic diseases,
```

## Arms

- **3D laparoscope** (EXPERIMENTAL) — For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
- **2D laparoscope** (EXPERIMENTAL) — For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.

## Interventions

- **3D laparoscope** (PROCEDURE) — For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
- **2D laparoscope** (PROCEDURE) — For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.

## Primary Outcomes

- **Amount of operative blood loss** _(time frame: At the time of surgery)_ — Amount of operative blood loss was measured by the anesthesiologists after defining it as the difference between the total amount of suction and irrigation plus the difference between the total gauze weight before and after surgery.

## Secondary Outcomes

- **Operative time** _(time frame: At the time of surgery)_

## Locations (1)

- Kangbuk Samsung Hospital, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.kangbuk samsung hospital|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04070872.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04070872*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*